Individualized Controlled Ovarian Stimulation: Biomarker-Guided Treatment Personalization
|
|
- Lee Malone
- 6 years ago
- Views:
Transcription
1 WHITE PAPER Individualized Controlled Ovarian Stimulation: Biomarker-Guided Treatment Personalization Author: Antonio La Marca, MD, PhD, Clinica Eugin and University of Modena and Reggio Emilia, Modena, Italy Antonio La Marca is a Professor of Obstetrics and Gynecology at the University of Modena and Reggio Emilia, as well as a coordinator of clinical activity at Clinica Eugin in Modena, Italy. Prof La Marca s clinical activity broadly covers the field of Reproductive Medicine and Surgery. His current scientific interests revolve around ovarian reserve and the pharmacological manipulation of ovarian activity. He has authored or co-authored more than 160 articles published in peer-reviewed journals, as well as several chapters of national and international textbooks. Prof La Marca has been an invited speaker at more than 100 international congresses. He has also been a Principal Investigator for a number of Phase 3 and 4 trials, as well as a recipient of several research grants. He is an active member of many national and international professional and scientific societies, and a consultant on infertility-related issues for the Italian Ministry of Health. Acknowledgements The scientific content and opinions presented in this paper are solely the views of Prof Antonio La Marca. The author thanks Ileana Stoica, PhD and Antonio Alvau, PhD from Green Park Content for their assistance in writing the manuscript. Financial support to Green Park Content was provided by Merck KGaA, Darmstadt, Germany. DISCLOSURE Honoraria for lectures and unrestricted research grants from Merck, MSD, Ferring, TEVA, IBSA, Beckman-Coulter, and Roche. A combination of biomarkers might increase clinicians predictive ability [...] and their ability to identify those patients at risk of poor or hyper ovarian response. Biomarkers: key tool of modern medicine Biomarkers have been defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention [1]. Due to their predictive power, biomarkers are used in modern medicine to support disease diagnosis and prognosis; guide the choice of targeted therapy [2]; define treatment response; assess the potential for drug-drug interactions; and adjust drug doses to optimize the benefit/risk profile [3]. The availability of biomarker testing has helped to reduce patients exposure to ineffective experimental treatments and identify surrogate outcomes for clinical trials [1]. 1 Biomarkers for Individualizing ART
2 Biomarkers and Assisted Reproductive Technologies (ART) In assisted reproduction, the diversity of the patient population and the expanding number of treatment options have created both a need and an opportunity for personalizing treatment [4]. Similar to other fields, reproductive medicine benefits from the use of biomarkers to evaluate the inter-variability between different sub-fertile populations and match the correct treatment plan to the individual patient profile [4]. IVF after a single cycle [7]. While the physical and psychological burden of treatment was the main cause of drop-out, 6% of those who discontinued did so due to inadequate response to treatment [7]. In my daily clinical activity, I always try to personalize the treatment for each patient [...] by choosing between different GnRH analogues [...] different types of gonadotropin and, most importantly, selecting the FSH starting dose. Biomarker-guided strategies for optimizing ovarian stimulation Need for treatment personalization One of the main roles of biomarkers in ART is to support an individualized approach to ovarian stimulation, which can offer women the optimal treatment regimen according to their characteristics while minimizing iatrogenic risks such as Ovarian Hyperstimulation Syndrome (OHSS) [5]. Biomarkers are being utilized to define the right drugs and doses for the right patient, thus maximizing the safety and efficacy of ART, including in the context of individualized Controlled Ovarian Stimulation (icos) [6]. The starting dose of gonadotropins is a key factor determining the outcome of Controlled Ovarian Stimulation (COS) and of overall IVF success [5]. Using a one size fits all strategy, with a standard gonadotropin dose, has been associated with a high degree of inter-individual variability in ovarian response rates, including abnormal (hypo or hyper) responsiveness [5]. This contributes to the high rate of treatment discontinuation observed in fertility patients: a Dutch study found that 9% of couples abandon Markers of ovarian reserve Ovarian reserve is defined as the number and quality of follicles left in the ovaries at any given time [8]. While the age of a woman is typically a good predictor of her ovarian reserve, and thus of COS response, the extent to which ovarian reserve declines with age varies considerably. The use of predictive biomarkers in addition to age can help identify patients with diminished or adequate reserve and tailor the treatment dose to maximize oocyte retrieval and thus the ART yield in each of these groups [8, 9]. Historically, a number of markers of ovarian response have been associated with ovarian reserve, including age, body weight, and hormonal biomarkers such as circulating Follicle Stimulating Hormone (FSH) and inhibin-b. However, since these are indirect markers of ovarian reserve, their predictive power is limited and varies substantially among patients or within the menstrual cycle of a single patient [9]. A tale of two markers Clinical evidence accumulated over the past decade or so has made a compelling argument for the use of antral follicle count (AFC) and anti-müllerian hormone (AMH) as preferred markers of ovarian reserve [9]. 2 Biomarkers for Individualizing ART
3 AFC is a functional biomarker measuring the number of antral follicles, as detected by transvaginal ultrasound [4]. The AFC analysis is relatively easy to perform, non-invasive, widely accessible in clinical practice, and provides immediate results [9]. However, the number of follicles identified is sonographer- and operator-dependent, which may impact standardization of results in multi-center trials [9-11]. Granulosa cells secrete AMH during the early stages of follicular maturation; therefore, circulating levels of this hormone are associated with the number of recruitable pre-antral and early antral follicles [10, 11]. Despite some variability within and between cycles, which is consistent with its physiological role in follicle development, the AMH assay has good consistency and reproducibility, and can be performed at any time during the menstrual cycle [9]. However, unlike AFC, it does not provide results in real time. Furthermore, the lack of an international standard means the measurements from different commercially available assays might be inconsistent, limiting the reliability of AMH as a biomarker [9, 11]. Clinical context A prospective study on 42 healthy women undergoing oophorectomy for benign indications established that the ovarian AFC and serum levels of AMH were significantly correlated with the ovarian primordial follicle number [12]. The same study found a weak albeit significant relationship between FSH and follicle numbers, which may explain the superiority of AFC/AMH over the older biomarkers [12]. From a clinical viewpoint, the superior predictive ability of AFC/AMH vs. traditional markers was confirmed in systematic reviews of clinical studies in infertile patients [5, 8, 13]. For example, an analysis of 41 and 25 studies investigating the predictive power of AMH and AFC, respectively, demonstrated that both markers were superior to FSH, allowed for the prediction of the entire spectrum of ovarian response, and could be used interchangeably in clinical practice [5]. In the past, we mainly used fixed doses of gonadotropins in our IVF patients, or sometimes we just looked at female age [...] but this is not completely correct because ovarian response is largely dependent on ovarian reserve. [...]. That is why you must personalize the treatment. In order to personalize the treatment dose, ovarian reserve must be measured for each patient [...] using the best markers available, AMH and AFC. Biomarker-guided dose tailoring in clinical practice Both AFC and AMH are relevant in clinical practice and are used individually as well as in combination [5]. Furthermore, clinical evidence to date suggests an important role for both biomarkers in the fine-tuning of gonadotropin doses and the development of personalized COS protocols [5, 14]. A number of post-hoc analyses of randomized controlled trials (RCTs) indicated that using a single marker, rather than both in combination, may be sufficient in clinical practice [15, 16]. At the same time, it must be recognized that women with extremes of ovarian reserve are typically not enrolled in RCTs, leading to gaps in our current understanding of treatment response patterns in real-world IVF patients. Real-world studies to date have confirmed the superiority of AFC/AMH to traditional markers, while also suggesting that combining the two may improve the overall predictive ability compared with using either biomarker alone [17]. Based on the cumulative evidence for the utility of AFC and AMH, two nomograms for calculating the FSH starting dose have been developed, based on either AMH or AFC plus age and Day 3 serum FSH (d3fsh) levels. In both models, AMH and AFC were found as the leading predictor. However, the introduction of d3fsh and age in the calculation improved prediction accuracy nonetheless [14, 18]. 3 Biomarkers for Individualizing ART
4 Emerging results and outstanding questions A recent multi-center, non-inferiority RCT compared clinical outcomes in 1,326 women randomized 1:1 to receive individualized, AMH-based follitropin delta or fixed-dose (150 IU) ovarian stimulation with follitropin alfa [19]. The trial showed similar efficacies for the two interventions, as measured by the primary endpoint of ongoing pregnancy rate. However, analysis of secondary outcome measures revealed that fewer women receiving an individualized FSH dose had extreme ovarian responses than those in the fixed-dose group. No difference in all-grade OHSS between treatment arms was observed, although women treated with individualized follitropin delta had a reduced need for OHSS preventive measures [19]. These results strengthen the argument for individualizing the FSH starting dose using biomarkers, as a way to reduce the rates of low and high responders and the need for OHSS-preventive strategies. In addition, these findings appear to be related to the treatment strategy dose personalization and not the type of FSH used. The selection of the FSH starting dose is a key factor affecting the outcome of COS. 1 FSH dosage nomograms make use of three variables: age, Day 3 serum FSH dose, and a marker of ovarian reserve either AFC or AMH to individualize the FSH starting dose to the patient characteristics. 2,3 63% VS. 42% of women in the nomogram group of women in the control group* 4 Frequency Optimal response Number of oocytes Frequency of retrieved oocytes in the nomogram group and control group. A recent RCT with follitropin alfa showed that using a nomogram to select the FSH starting dose resulted in a significant increase in the proportion of patients with the target number of retrieved oocytes.** 4 * P= ** Defined as 8-14 oocytes AFC=antral follicle count; AMH=anti-Müllerian hormone; COS=controlled ovarian stimulation; FSH=follicle stimulating hormone. 1. La Marca A and Sunkara SK. Hum Reprod Update 2014;20: ; 2. La Marca A, et al. J Ovarian Res 2013;6:11; 3. La Marca A, et al. BJOG 2012;119: ; 4. Allegra A, et al. Reprod Biomed Online doi: /j.rbmo Biomarkers for Individualizing ART
5 Indeed, a recent RCT confirmed that individualizing the FSH starting dose in IVF/ICSI cycles, compared to fixed-dose stimulation based on age and using the same compound, had a measurable impact on treatment outcomes [20]. In this two- arm, prospective trial of 194 couples attending their first IVF/ICSI in the clinic, patients were randomized to receive either a fixed starting dose of follitropin alfa or an individualized dose of follitropin alfa using an AMH-based nomogram. The proportion of patients with target ovarian response, defined as 8 14 retrieved oocytes, was 63% in the nomogram group and 42% in the control group, a difference that was statistically significant (P=0.0037) [20]. Furthermore, clinical pregnancy rates per embryo transfer were 48% in patients with target ovarian response vs. 27% in those not achieving the target ovarian response [21]. While further research is needed to assess the effects of a biomarker-guided, personalized approach on live birth outcomes, these results suggest that tailoring the FSH starting dose with the help of biomarkers can be a valuable strategy for optimizing COS outcomes. Toward an integrated perspective on fertility biomarkers A wealth of evidence accumulated over the past decade supports the use of fertility biomarkers to optimize ART outcomes. Both AFC and AMH have a role in predicting ovarian response and guiding treatment decisions [5, 9]. Nomograms based on AFC/AMH have been developed to tailor the starting dose of gonadotropin, a strategy that has been shown to improve COS outcomes while decreasing risk for patients [5]. Due to recent advances in the underlying technologies, the standardization issues that have limited the use of AMH and AFC in the past may soon be overcome, leading to a synergistic approach that utilizes both biomarkers in the fertility treatment algorithm [9, 10]. Future treatment algorithms may employ a truly integrated strategy that combines a range of markers to design COS protocols that meet individual patient characteristics and treatment needs [4]. AMH and AFC are widely used in clinical practice [...] and recently an Italian survey showed that 89% of Italian clinicians measure both AMH and AFC to personalize treatment, prevent OHSS, improve clinical performance [...] and reduce drop-out. 5 Biomarkers for Individualizing ART
6 References 1. Strimbu K, Tavel JA. What are biomarkers? Current Opin HIV AIDS. 2010;5(6): Renfro LA, An MW, Mandrekar SJ. Precision oncology: A new era of cancer clinical trials. Cancer Lett. 2017;387: Marquet P, Longeray PH, Barlesi F; and participants of round table N 1 of Giens XXX. Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science? Therapie. 2015;70(1): Alviggi C, Humaidan P, Ezcurra D. Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols. Reprod Biol Endocrinol. 2012;10:9. 5. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014;20(1): Bosch E, Ezcurra D. Individualised controlled ovarian stimulation (icos): maximising success rates for assisted reproductive technology patients. Reprod Biol Endocrinol. 2011;9: Verberg MF, Eijkemans MJ, Heijnen EM, et al. Why do couples drop-out from IVF treatment? A prospective cohort study. Hum Reprod Sep;23(9): Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12(6): Fleming R, Seifer DB, Frattarelli JL, Ruman J. Assessing ovarian response: antral follicle count versus anti-müllerian hormone. Reprod Biomed Online. 2015;31(4): Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-müllerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update. 2015;21(6): Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril. 2013;99(4): Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril. 2011;95(1): Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update. 2011;17(1): La Marca A, Grisendi V, Giulini S, et al. Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count. J Ovarian Res. 2013;6(1): Andersen AN, Witjes H, Gordon K, Mannaerts B; and the Xpect investigators. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rfsh/gnrh antagonist protocol with or without oral contraceptive pre-treatment. Hum Reprod. 2011;26(12): Broekmans FJ, Verweij PJ, Eijkemans MJ, Mannaerts BM, Witjes H. Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2014;29(8): Al-Azemi M, Killick SR, Duffy S, et al. Multi-marker assessment of ovarian reserve predicts oocyte yield after ovulation induction. Hum Reprod. 2011;26(2): La Marca A, Papaleo E, Grisendi V, Argento C, Giulini S, Volpe A. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles. BJOG. 2012;119(10): Andersen NA, Nelson SM, Fauser BC, García-Velasco JA, Klein BM, Arce JC; and the ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017;107(2): Allegra A, Marino A, Volpes A, et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reprod Biomed Online. 2017;34(4): Marino A, Allegra A, Volpes A, et al. A predictive nomogram based on multiple biomarkers leads to appropriate rfsh starting dose in IVF/ICSI cycles: a randomized controlled trial. Hum Reprod. 2016; 31 (suppl 1) i327. (Abstracts of the 32nd annual meeting of ESHRE, Helsinki, Finland, 3 July - 6 July, 2016). GBPMLR/GON/0517/0013a Date of preparation: May Biomarkers for Individualizing ART
Prognosticating ovarian reserve by the new ovarian response prediction index
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Tak A et al. Int J Reprod Contracept Obstet Gynecol. 2018 Mar;7(3):1196-1200 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20180917
More informationIndividualized treatment based on ovarian reserve markers
Individualized treatment based on ovarian reserve markers Prof Dr. Nikolaos P. Polyzos M.D. PhD Professor and Medical Co- Director, Vrije Universiteit Brussel, UZ Brussel, Belgium Professor of Reproduc?ve
More informationlbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour
lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate
More informationIndividualization of the FSH starting dose in IVF/ ICSI cycles using the antral follicle count
La Marca et al. Journal of Ovarian Research 2013, 6:11 RESEARCH Open Access Individualization of the FSH starting dose in IVF/ ICSI cycles using the antral follicle count Antonio La Marca 1*, Valentina
More informationPoor & Hyper responders: what is the best approach?
Poor & Hyper responders: what is the best approach? A. La Marca ObGyn Dept University of Modena and Reggio Emilia Italy Center for Reproductive Medicine University Hospital of Modena Italy Criteria used
More informationJMSCR Vol 06 Issue 09 Page September 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i9.53 Role of Anti-Mullerian Hormone
More informationCOMPARING AMH, AFC AND FSH FOR PREDICTING HIGH OVARIAN RESPONSE IN WOMEN UNDERGOING ANTAGONIST PROTOCOL
COMPARING AMH, AFC AND FSH FOR PREDICTING HIGH OVARIAN RESPONSE IN WOMEN UNDERGOING ANTAGONIST PROTOCOL Nguyen Xuan Hoi1, Nguyen Manh Ha2 1 National Obstetrics and Gynecology Hospital, 2Hanoi Medical Unviversity
More informationThe emergence of Personalized Medicine protocols for IVF.
Individualising IVF: Introduction to the POSEIDON Concept Introduction The emergence of Personalized Medicine protocols for IVF. Differences between patients: age, ovarian reserve, BMI or presence of ovarian
More informationResearch Article. Jayakrishnan Krishnakumar 1, Akansha Agarwal 1, Divya Nambiar 1, Shankar Radhakrishnan 2 *
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Krishnakumar J et al. Int J Reprod Contracept Obstet Gynecol. 2016 Aug;5(8):2762-2767 www.ijrcog.org pissn 2320-1770 eissn
More informationPersonalizing ovarian stimulation for IVF
Personalizing ovarian stimulation for IVF Biljana Popovic-Todorovic MD,PhD Centre for Reproductive Medicine UZ Brussel QuickTime and are needed to see this picture. Controlled ovarian stimulation for IVF/ICSI
More informationPredictive factors for ovarian response in a corifollitropin alfa/gnrh antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles
Oehninger et al. Reproductive Biology and Endocrinology (2015) 13:117 DOI 10.1186/s12958-015-0113-1 RESEARCH Open Access Predictive factors for ovarian response in a corifollitropin alfa/gnrh antagonist
More informationBiomarkers for Prediction of Pregnancy Outcome in Fertility Patients. Scott Nelson Muirhead Chair in Obstetrics & Gynaecology
Biomarkers for Prediction of Pregnancy Outcome in Fertility Patients Scott Nelson Muirhead Chair in Obstetrics & Gynaecology Why do we need to know ovarian response? Anna Sarah Just do IVF and see response
More informationComparison of anti-mullerian hormone and antral follicle count for assessment of ovarian reserve
Original Article Comparison of anti-mullerian hormone and antral follicle count for assessment of ovarian reserve Sonal Panchal, Chaitanya Nagori Dr. Nagori s Institute for Infertility and IVF, Ellisbridge,
More informationNomogram to predict the number of oocytes retrieved in controlled ovarian stimulation
ORIGINAL ARTICLE http://dx.doi.org/.63/cerm.216.43.2.112 pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 216;43(2):112-118 Nomogram to predict the number of oocytes retrieved in controlled ovarian
More informationFollicle-stimulating hormone/luteinizing hormone ratio as an independent predictor of response to controlled ovarian stimulation
Follicle-stimulating hormone/luteinizing hormone ratio as an independent predictor of response to controlled ovarian stimulation Aim: To determine whether a follicle-stimulating hormone (FSH)/luteinizing
More informationAMH CUT-OFF VALUES FOR PREDICTING OVARIAN RESPONSE IN IVF. Nguyễn Xuân Hợi, MD, PhD Hoàng Văn Hùng MsC, MD
AMH CUT-OFF VALUES FOR PREDICTING OVARIAN RESPONSE IN IVF Nguyễn Xuân Hợi, MD, PhD Hoàng Văn Hùng MsC, MD INTRODUCTION Ovarian stimulation is an important process in IVF treatment, aiming at obtain a number
More informationHigh ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol
Human Reproduction, Vol.28, No.2 pp. 442 452, 2013 Advanced Access publication on November 7, 2012 doi:10.1093/humrep/des389 ORIGINAL ARTICLE Reproductive endocrinology High ovarian response does not jeopardize
More information- Meta. : (rfsh); (ufsh); (IVF); : R711.6 : A : X(2015) : hmg( FSH LH) [ufsh, (ufsh-p) (ufsh-hp)] (rfsh) [1] 80, rfsh, 90, :
35 2 Vol.35 No.2 2015 2 Feb. 2015 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2015.02.0099 E-mail: randc_journal@163.com (FSH) - Meta FSH ( 400010) : (IVF) (ICSI) (rfsh) (ufsh) (COS) : PubMed
More informationEvaluation of ovarian response prediction according to age and serum AMH levels in IVF cycles: a retrospective analysis
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Pillai SM et al. Int J Reprod Contracept Obstet Gynecol. 2017 Aug;6(8):3306-3310 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20173190
More informationAdvanced age, poor responders and the role of LH supplementation. C. Alviggi University Federico II, Naples, Italy
Advanced age, poor responders and the role of LH supplementation C. Alviggi University Federico II, Naples, Italy LH serum level (IU/L) 20.0 15.0 10.0 5.0 0.0 LH levels during spontaneous and stimulated
More informationNGUYEN QUOC ANH. M.D., M.Sc. Tu Du Hospital Vietnam
NGUYEN QUOC ANH M.D., M.Sc. Tu Du Hospital Vietnam FULLY AUTOMATED AMH TESTING OF OVARIAN RESPONSE IN IVF NGUYỄN QUỐC ANH MD. Infertility dep. Tudu hospital Index What is AMH? Standard AMH testing Fully
More informationThe ovarian response resulting
Comparison of antim ullerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two
More informationCorifollitropin alfa or rfsh treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial
Leader et al. Reproductive Biology and Endocrinology 2013, 11:52 RESEARCH Open Access Corifollitropin alfa or rfsh treatment flexibility options for controlled ovarian stimulation: a post hoc analysis
More informationENDOCRINE CHARACTERISTICS OF ART CYCLES
ENDOCRINE CHARACTERISTICS OF ART CYCLES DOÇ. DR. SEBİHA ÖZDEMİR ÖZKAN KOCAELI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, IVF UNIT 30.04.2014, ANTALYA INTRODUCTION The endocrine
More informationQuestions. Ultrasound markers of ovarian reserve Modena April 18-19, Your choice is.. Impact study: stop OR tests or Soft catheters??
Ultrasound markers of ovarian reserve Modena April 18-19, 2008 Frank J Broekmans Reproductive Medicine UMC Utrecht Impact study: stop OR tests or Soft catheters?? Stop OR screening, cost reduction 21 euro
More informationBest practices of ASRM and ESHRE
Best practices of ASRM and ESHRE Late submission Cortina d Ampezzo, Italy 1-3 March 2012 A joint meeting between the American Society for Reproductive Medicine and the European Society of Human Reproduction
More informationTitle: Authors: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
More informationEffect of ovarian stimulation on oocyte quality and embryonic aneuploidy: a prospective, randomised controlled trial
FULL PROJECT TITLE: Effect of ovarian stimulation on oocyte quality and embryonic aneuploidy: a prospective, randomised controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM)
More informationMilder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization
Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background
More informationAntral follicle count as a predictor of ovarian response
Original article Antral follicle count as a predictor of ovarian response N. Lonegro a, N. Napoli a,*, R. Pesce b and C. Chacón a a Imaging Department, Hospital Italiano de Buenos Aires, Ciudad Autónoma
More informationPOSEIDON s stratification of Low prognosis patients in ART and its new proposed marker of successful outcome: The WHY, the WHAT, and the HOW
POSEIDON s stratification of Low prognosis patients in ART and its new proposed marker of successful outcome: The WHY, the WHAT, and the HOW Sandro C. Esteves, MD., PhD. I. The WHY The management of patients
More informationInfluence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser
Influence ovarian stimulation on oocyte and embryo quality Prof.Dr. Bart CJM Fauser How to balance too much vs too little? Lecture Outline Context ovarian stimulation Impact ovarian stimulation on oocyte
More informationSTIMULATION AND OVULATION TRIGGERING
STIMULATION AND OVULATION TRIGGERING Professor IOANNIS E. MESSINIS MD, PhD (Aberdeen, UK), FRCOG (UK) Department of Obs/Gynae University of Thessaly Larissa, GREECE DISCLOSURE Nothing to disclose Learning
More informationInfertility in Women over 35. Alison Jacoby, MD Dept. of Ob/Gyn UCSF
Infertility in Women over 35 Alison Jacoby, MD Dept. of Ob/Gyn UCSF Learning Objectives Review the effect of age on fertility Fertility counseling for the patient >35 - timing - lifestyle - workup Fertility
More informationLOW RESPONDERS. Poor Ovarian Response, Por
LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients
More informationThe association between anti-müllerian hormone and IVF pregnancy outcomes is influenced by age
Reproductive BioMedicine Online (2010) 21, 757 761 www.sciencedirect.com www.rbmonline.com ARTICLE The association between anti-müllerian hormone and IVF pregnancy outcomes is influenced by age Jeff G
More informationMinimising IVF related mortality and morbidity. Scott Nelson Muirhead Professor in Obstetrics & Gynaecology
Minimising IVF related mortality and morbidity Scott Nelson Muirhead Professor in Obstetrics & Gynaecology We rarely say no - so what I will cover today VTE as an example of a modifiable IVF complication
More informationUsing AMH for determining a stratified gonadotropin dosing regimen for IVF/ICSI and optimizing outcomes
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
More informationPUBLISHED SCIENTIFIC EVIDENCE ON THE USE OF ANTI-MÜLLERIAN HORMONE. Anti-Müllerian Hormone (AMH)
PUBLISHED SCIENTIFIC EVIDENCE ON THE USE OF ANTI-MÜLLERIAN HORMONE Anti-Müllerian Hormone (AMH) Table of Contents» Fertility Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction
More informationLuteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationAge specific serum anti-müllerian hormone levels in 1,298 Korean women with regular menstruation
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2011;38(2):93-97 Age specific serum anti-müllerian hormone levels in 1,298 Korean women with regular menstruation Ji Hee Yoo, Hye Ok
More informationGrynnerup et al. Reproductive Biology and Endocrinology (2019) 17:11
Grynnerup et al. Reproductive Biology and Endocrinology (2019) 17:11 https://doi.org/10.1186/s12958-019-0452-4 RESEARCH Prediction of the lower serum anti- Müllerian hormone threshold for ovarian stimulation
More information2017 United HealthCare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1143-4 Program Prior Authorization/Notification Medication Menopur (menotropins) * P&T Approval Date 8/2014, 5/2015, 5/2016, 5/2017
More informationThrombosis during assisted reproduction. Scott Nelson Muirhead Chair in Obstetrics & Gynaecology
Thrombosis during assisted reproduction Scott Nelson Muirhead Chair in Obstetrics & Gynaecology ART can be as safe as natural pregnancy!! What used to be the risk of thrombosis in ART!! We can use AMH
More informationA multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of
A multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of Endometrioma and deep infiltrating endometriosis Professor C. Chapron and the Group
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
More informationDr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain. Declared no potential conflict of interest
Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain Declared no potential conflict of interest Is there a role for LH in elderly patients? Dr. Ernesto Bosch Instituto Valenciano de Infertilidad.
More informationScientific Highlights: First world conference on luteinizing hormone in ART: Landing in Asia Pacific
This EXCEMED conference followed on from the First world conference on luteinizing hormone (LH) in ART, which took place in Naples in May 2016. Bringing the topic of LH to Asia Pacific provided an opportunity
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationAnti-Mullerian Hormone as a Predictive Factor in Assisted Reproductive Technique of Polycystic Ovary Syndrome Patients
ORIGINAL REPORT Anti-Mullerian Hormone as a Predictive Factor in Assisted Reproductive Technique of Polycystic Ovary Syndrome Patients Ashraf Aleyasin, Marzie Aghahoseini, Sara Mokhtar, and Parvin Fallahi
More informationIs it the seed or the soil? Arthur Leader, MD, FRCSC
The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events
More informationL6: DuoStim: the alternative of oocytes/embryos accumulation programs Carlo Alviggi
L6: DuoStim: the alternative of oocytes/embryos accumulation programs Carlo Alviggi Italy What is the aim of IVF? What is the measure of success in IVF? Cumulative live birth rate per started cycle Live
More informationR-Recent Advance in Patient Friendly Protocol
R-Recent Advance in Patient Friendly Protocol Somjate Manipalviratn, M.D. Reproductive Endocrinologist and Infertility Specialist Clinical Director Superior A.R.T., Bangkok, Thailand Objective of ovarian
More informationORIGINAL ARTICLE Reproductive endocrinology. A. Nyboe Andersen 1, H. Witjes 2, K. Gordon 3, and B. Mannaerts 4, * on behalf of the Xpect investigators
Human Reproduction, Vol.26, No.12 pp. 3413 3423, 2011 Advanced Access publication on September 27, 2011 doi:10.1093/humrep/der318 ORIGINAL ARTICLE Reproductive endocrinology Predictive factors of ovarian
More informationAnti-Mullerian hormone (AMH) as predictor of ovarian reserve
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Shembekar CA et al. Int J Reprod Contracept Obstet Gynecol. 2017 Sep;6(9):4006-4010 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20174053
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
More informationAssociation of ovarian reserve with age, BMI and serum FSH level in subfertile women
409 ORIGINAL ARTICLE Association of ovarian reserve with age, BMI and serum FSH level in subfertile women Sarwat Jehan, 1 Sadiqa Syed 2 Abstract Objective: To examine the association of age, body mass
More informationA comparative study between agonist and antagonist protocol for ovarian stimulation in art cycles at a rural set up in South Gujarat
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Nadkarni PK et al. Int J Reprod Contracept Obstet Gynecol. 2015 Jun;4(3):617-621 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationIn Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome
Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,
More informationAge-Specific Serum Anti-Mullerian Hormone and Follicle Stimulating Hormone Concentrations in Infertile Iranian Women
Original Article Age-Specific Serum Anti-Mullerian Hormone and Follicle Stimulating Hormone Concentrations in Infertile Iranian Women Alireza Raeissi, M.Sc. 1, Alireza Torki, M.Sc. 1, Ali Moradi, Ph.D.
More informationMedicine, University of Glasgow, Glasgow, United Kingdom; and c The Fertility Clinic, Odense University Hospital, Odense, Denmark
Does the time interval between antim ullerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization intracytoplasmic sperm injection cycles
More informationHonorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive FIGO s Distinguished Merit Award for Services towards women s health.
Prof.Duru Shah Founder President The PCOS Society (India) President Elect of the Indian Society for Assisted Reproduction (ISAR) Honorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive
More informationInfertility Clinical Guideline
Infertility Clinical Guideline Ovarian Stimulation Guideline Purpose: To provide sufficient background regarding various ovarian stimulation protocols for In Vitro Fertilization cycles. Goal: To assist
More informationExternal validation of anti-müllerian hormone based prediction of live birth in assisted conception
Khader et al. Journal of Ovarian Research 2013, 6:3 RESEARCH Open Access External validation of anti-müllerian hormone based prediction of live birth in assisted conception Amani Khader 1, Suzanne M Lloyd
More informationOvarian hyperstimulation syndrome (OHSS)
Ovarian hyperstimulation syndrome (OHSS) OHSS OHSS: exaggerated response to gonadotropins and hcg Characterized by: ovarian enlargement increased vascular permeability fluid accumulation in abdomen Associated
More informationInternational Journal of Pharma and Bio Sciences ENDOCRINE MARKERS AND DECLINE IN REPRODUCTIVE POTENTIAL OF WOMEN ABSTRACT
Research Article Biochemistry International Journal of Pharma and Bio Sciences ISSN 0975-6299 ENDOCRINE MARKERS AND DECLINE IN REPRODUCTIVE POTENTIAL OF WOMEN BUSHRA FIZA *, 1, 2, RATI MATHUR 2, MAHEEP
More informationNumber of oocytes and live births in IVF
Number of oocytes and live births in IVF Dr Sesh K Sunkara MD, MRCOG Royal Marsden Hospital, London Kings Healthcare Partners (Guy s & St Thomas NHS Foundation Trust), London, UK Background IVF results
More informationA prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF
FVV IN OBGYN, 2012, 4 (2): 82-87 Original paper A prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF S. GORDTS,
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years
More informationDipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche. Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare
Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare Carlo Alviggi The rational of Follicular synchronization
More informationAntral follicle count in clinical practice: analyzing clinical relevance
CONTROVERSY I Antral follicle count in clinical practice: analyzing clinical relevance Albert Hsu, M.D., Margaret Arny, Ph.D., Alexander B. Knee, M.S., Carrie Bell, M.D., Elizabeth Cook, Ph.D., Amy L.
More informationAgonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
More informationEndometrial thickness affects the outcome of in vitro fertilization and embryo transfer in normal responders after GnRH antagonist administration
Wu et al. Reproductive Biology and Endocrinology 2014, 12:96 RESEARCH Open Access Endometrial thickness affects the outcome of in vitro fertilization and embryo transfer in normal responders after GnRH
More informationA new ovarian response prediction index (ORPI): implications for individualised controlled ovarian stimulation
Oliveira et al. Reproductive Biology and Endocrinology 2012, 10:94 RESEARCH Open Access A new ovarian response prediction index (ORPI): implications for individualised controlled ovarian stimulation Joao
More informationWhat is the value of anti-müllerian hormone in predicting the response to ovarian stimulation with GnRH agonist and antagonist protocols?
Knez et al. Reproductive Biology and Endocrinology (2015) 13:58 DOI 10.1186/s12958-015-0049-5 RESEARCH Open Access What is the value of anti-müllerian hormone in predicting the response to ovarian stimulation
More informationIVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW
IVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW Jon Havelock, MD, FRCSC, FACOG Co-Director - PCRM Disclosure No conflict of interest in relation
More informationBrief Report. What s Known. Keywords Melatonin Ovarian reserve Assisted reproductive techniques Embryo Oocytes. What s New.
IJMS Vol 4, No 1, January 017 Brief Report Effect of Melatonin on the Outcome of Assisted Reproductive Technique Cycles in Women with Diminished Ovarian Reserve: A Double-Blinded Randomized Clinical Trial
More informationAndrogen supplementation in women with low functional ovarian reserve
Androgen supplementation in women with low functional ovarian reserve Norbert Gleicher, MD Medical Director and Chief Scientist, Center For Human Reproduction, New York, NY President, Foundation For Reproductive
More informationNo association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH
Reproductive BioMedicine Online (2011) 23, 457 465 www.sciencedirect.com www.rbmonline.com ARTICLE No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant
More informationIntérêt de l hcg et induction de l ovulation. Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium
Intérêt de l hcg et induction de l ovulation Christophe Blockeel, MD, PhD Centre for Reproductive Medicine, Brussels, Belgium Conflict of interest The opinions expressed in this document are the opinions
More informationL2. Optimising IVF outcomes through increased number of oocytes... 03
SCIENTIFIC HIGHLIGHTS EXCEMED Blended Education Ovarian stimulation strategies: maximizing efficiency in ART Rio de Janeiro, Brazil 6-7 April 2018 Preface Success rates following IVF treatment have increased
More informationGynecology & Reproductive Health
Research Article Gynecology & Reproductive Health ISSN 2639-9342 Effects of Human Immunodeficiency Virus Infection and Antiretroviral Therapy on Ovarian Reserve and Invitro Fertilisation Success Mohamed
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More informationBACKGROUNDER. Pregnitude A Fertility Dietary Supplement for Reproductive Support Offers an Additional Option for Women Who Are Trying to Conceive
BACKGROUNDER Pregnitude A Fertility Dietary Supplement for Reproductive Support Offers an Additional Option for Women Who Are Trying to Conceive Studies find that increased chances of ovulation, menstrual
More informationThe Significance of Low Anti-Müllerian Hormone Levels in Young Women Undergoing in Vitro Fertilization
The Significance of Low Anti-Müllerian Hormone Levels in Young Women Undergoing in Vitro Fertilization Caitlin Haswell, M.D., Estil Strawn, Jr., M.D., Aniko Szabo, Ph.D., Joseph Davis, D.O., and Kate D.
More informationRaoul Orvieto. The Chaim Sheba Medical Center Tel Hashomer, Israel. Declared no potential conflict of interest
Raoul Orvieto The Chaim Sheba Medical Center Tel Hashomer, Israel Declared no potential conflict of interest LH in antagonist cycles; is the story really written? Raoul Orvieto M.D. Israel Overview Role
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 September 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 September 2010 100 µg/0.5 ml, solution for injection B/1 prefilled syringe + 1 needle (CIP code: 374 590-1) 150
More informationCorifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis
Fensore et al. Journal of Ovarian Research (05) 8: DOI 0.86/s048-05-060-4 REVIEW compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis Stefania Fensore, Marco
More informationWhat is the POSEIDON concept?
Improving Success in ART: how to define it and key strategies to get the best outcomes, Kiev, 21-09-2018 What is the POSEIDON concept? Alessandro Conforti Italy Objectives Unravel the definition of POR
More informationUtility of Estradiol as a Predictive Marker of Ovarian Hyper Stimulation Syndrome
Research Article imedpub Journals http://www.imedpub.com/ Annals of Clinical and Laboratory Research DOI: 10.21767/2386-5180.1000167 Utility of Estradiol as a Predictive Marker of Ovarian Hyper Stimulation
More informationArticle Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality?
RBMOnline - Vol 16. No 5. 2008 664-670 Reproductive BioMedicine Online; www.rbmonline.com/article/3179 on web 11 March 2007 Article Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality
More informationOngoing Pregnancy Rates in Women with Low and Extremely Low AMH Levels. A Multivariate Analysis of 769 Cycles
Ongoing Pregnancy Rates in Women with Low and Extremely Low AMH Levels. A Multivariate Analysis of 769 Cycles Alon Kedem 1 *, Jigal Haas 1, Liat Lerner Geva 2, Gil Yerushalmi 1, Yinon Gilboa 1, Hanna Kanety
More informationHow to supplement hypo-androgenic women correctly
How to supplement hypo-androgenic women correctly Norbert Gleicher, MD Medical Director and Chief Scientist, Center For Human Reproduction, New York, NY President, Foundation For Reproductive Medicine,
More informationManish Banker. Declared receipt of grants; member of a company advisory board, board of director or similar group
Manish Banker Nova IVI Fertility Pulse Women's Hospital Gujarat, India Declared receipt of grants; member of a company advisory board, board of director or similar group The Indian point of view Manish
More informationElonva (corifollitropin alfa): A simplified, patientfocused
Product Monograph (corifollitropin alfa): A simplified, patientfocused approach to controlled ovarian stimulation TABLE OF CONTENTS (corifollitropin alfa): A simplified, patientfocused approach to controlled
More information2015 Elsevier. Link to publisher version: doi: /j.fertnstert Deposited on: 23 June 2016
Nelson, S. M., Pastuszek, E., Kloss, G., Malinowska, I., Liss, J., Lukaszuk, A., Plociennik, L., and Lukaszuk, K. (2015) Two new automated, compared with two enzyme-linked immunosorbent, antimüllerian
More informationOvarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy
Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy M.E. Coccia, F. Cammilli, L. Ginocchini, F. Borruto* and F. Rizzello Dept Gynaecology Perinatology and Human
More informationGizzo et al. Reproductive Biology and Endocrinology (2015) 13:28 DOI /s
Gizzo et al. Reproductive Biology and Endocrinology (2015) 13:28 DOI 10.1186/s12958-015-0024-1 RESEARCH Open Access Menstrual cycle length: a surrogate measure of reproductive health capable of improving
More information